-
Jan 14, 2025, 08:17 AM
by
Record year comes as the rise of precision medicine drives a surge in demand
Full story
-
Jan 14, 2025, 08:17 AM
by
Ajay Gannerkote, an experienced healthcare leader with more than 20 years of demonstrated success driving industry growth and transformation, takes helm at global genomics company
Full story
-
Jan 14, 2025, 01:00 AM
by
User Not Found
Bio-IT World | An international team of researchers is delving into the molecular and cellular changes in muscle tissue associated with Chronic Fatigue Syndrome (CFS) and long COVID. The effort focuses on identifying biomarkers and pathways that could pave the way for diagnosis and treatment.
Full story
-
Jan 13, 2025, 09:00 AM
by
User Not Found
Bio-IT World | Among the many partnerships and technical announcements made by NVIDIA during the company's Monday morning presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry.
Full story
-
Jan 13, 2025, 08:15 AM
by
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
Full story
-
Jan 13, 2025, 08:15 AM
by
Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio’s proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy.
Full story
-
Jan 10, 2025, 08:28 AM
by
Full story
-
Jan 10, 2025, 08:28 AM
by
Biofidelity and CellCarta have announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.
Full story
-
Jan 10, 2025, 08:28 AM
by
STEMart introduces Balloon Catheter Testing Services for the development of safe and effective medical devices.
Full story
-
Jan 10, 2025, 08:28 AM
by
Coronado Research is pleased to announce the appointment of Jo Marshall as EVP of Data Services and Advanced Analytics.
Full story
-
Jan 9, 2025, 08:35 AM
by
ThirdLaw Molecular Inc., a targeted drug discovery biotech reimagining molecular therapeutics, today announced the launch of its first DNA-encoded library of 4.5 billion Spiroligomer™ macromolecules. This library provides the Company and prospective partners access to a revolutionary category of molecules and the potential to transform how diseases are diagnosed and treated
Full story
-
Jan 9, 2025, 08:35 AM
by
Bio-IT World Conference & Expo, the premier annual gathering of 3,000 innovators at the intersection of IT and life sciences, returns to Boston April 2-4, ready to meet participants’ demand for the latest information on cutting-edge technologies like generative AI, machine learning (ML), and quantum computing that promise to shape precision medicine and redefine patient outcomes.
Full story
-
Jan 9, 2025, 08:35 AM
by
Leica Biosystems and Indica Labs today announced that Leica Biosystems has agreed to make a significant strategic investment in Indica Labs.
Full story
-
Jan 9, 2025, 01:00 AM
by
User Not Found
Bio-IT World | Looming uncertainties tied to the upcoming U.S. administration change will affect many key areas of artificial intelligence (AI) in 2025, according to Mark Dredze, interim deputy director for the Data Science and AI Institute at Johns Hopkins University. While a focus on deregulation appears likely, exactly how things will play out for AI governance and policy is anyone’s guess.
Full story
-
Jan 8, 2025, 07:53 AM
by
Following an expanded collaboration between AI innovator Quris-AI and Merck KGaA and a two-year validation study to test clinical safety prediction by identifying drug candidate liver toxicity risks, it was announced this morning that Merck KGaA has adopted the startup's platform to test small molecule drug candidates prior to initiating clinical trials.
Quris-AI’s platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug-induced toxicities better.
Full story
-
Jan 8, 2025, 07:53 AM
by
ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the National Cancer Institute’s new Vanguard Study.
Full story
-
Jan 8, 2025, 01:00 AM
by
User Not Found
Bio-IT World | The placenta is a temporary but critical organ everyone needs to initiate their life, yet it remains one of the most understudied organs in human biology despite the possible lifelong health implications if anything it is supposed to do goes awry.
Full story
-
Jan 7, 2025, 01:00 AM
by
User Not Found
Bio-IT World | 2024 was full of innovative ideas and achievements. We spoke with industry experts and leaders about what to anticipate in the new year. Here are the full trends and predictions, including more on AI/ML, multimodal data, drug discovery, new policies, spatial biology, and more.
Full story
-
Jan 3, 2025, 01:00 AM
by
User Not Found
Bio-IT World | Last year, the world of biotech achieved much with AI, sequencing, treatment development, and more. The Trends from the Trenches podcast also covered data management strategies, embracing change, and the technologies driving data-intensive science. To kick off the new year, here are the top stories and top podcast episodes of 2024 from Bio-IT World and Trends from the Trenches.
Full story
-
Dec 30, 2024, 01:00 AM
by
User Not Found
Bio-IT World | What role will AI play in the future of drug development, especially as novel therapeutic approaches such as precision medicine drive up the complexity and cost of research? Some industry headlines hype AI as a magic bullet, capable of cutting through the headwinds of slow development cycles, shifting regulations, and high rates of failure. For companies racing to reach the market with safe and compliant new drug products, this vision of AI is compelling—and it’s driving heavy investment.
Full story